For Kaiser Permanente members in California seeking substance-use treatment outside Kaiser’s facility network. Kaiser operates as a closed-system HMO — most care is delivered inside Kaiser’s owned facilities. We pursue Single-Case Agreements (SCAs) and Continuity of Care exceptions to secure out-of-network coverage at our Northridge facility when Kaiser’s internal network can’t deliver the level or quality of care your clinical assessment requires.
Sometimes — but not by default. Kaiser Permanente is a closed-system integrated health plan: Kaiser owns its own hospitals, medical offices, and clinical staff, and Kaiser’s standard benefit structure covers care delivered inside that network. Out-of-network treatment at facilities like Gev’s Recovery is generally not in the standard benefit. The pathways that do exist are Single-Case Agreement (SCA) — a one-off contract Kaiser negotiates with an out-of-network provider when in-network options are inadequate — and Continuity of Care exceptions when a member is mid-treatment with a non-Kaiser provider. Both pathways require clinical-necessity documentation and active negotiation with Kaiser’s UM team.
If your card lists Kaiser Permanente, Kaiser Foundation Health Plan, or KP, this is the verification path that applies to you.
Inside Kaiser’s network, members have access to Kaiser’s own substance-use treatment programs — outpatient counseling, group therapy, MAT prescribing, intensive outpatient at Kaiser facilities, and inpatient detox or residential at Kaiser-contracted hospitals when Kaiser’s medical team determines it’s medically necessary. The structure is gatekept: a Kaiser primary care or behavioral-health provider typically must refer the member into the SUD treatment line.
Outside Kaiser’s network — at Gev’s Recovery or any non-Kaiser facility — coverage is contingent on either an SCA or a Continuity of Care exception:
Specific SCA outcomes depend on Kaiser’s UM determination, the strength of the clinical-necessity case, and the member’s existing relationship with Kaiser providers. Our team documents medical necessity at every checkpoint.
Authorization tells you what’s covered; the program decides whether it works. Kaiser members pursuing non-Kaiser treatment have already concluded that Kaiser’s internal options are not the right fit — geographically, clinically, or for family-system reasons. The treatment center receiving them needs to be ready to negotiate with Kaiser, not just bill Kaiser.
Authorization tells you what’s covered; the program decides whether it works.
Kaiser SCA work is fundamentally different from commercial-PPO utilization management. There’s no standing in-network agreement to operate inside; every authorization is negotiated case-by-case. Our utilization-review and billing team handles the SCA cycle from initial Kaiser engagement through external appeal if needed.
The decision to escalate is not commercial. It’s clinical. When a client is denied care that’s clinically indicated, we advocate for them — through every step above — to support coverage of the level of care our team believes is medically appropriate.
Kaiser Permanente operates under California’s HMO regulatory framework, which gives Kaiser members specific protections most commercial-PPO members don’t have.
When we appeal a Kaiser SCA denial, the appeal is built on the clinical documentation, federal MHPAEA, California SB 855, and the specific medical-necessity case for non-Kaiser treatment.
Industry standard says 28 days. The clinical literature on substance-use treatment outcomes says something different. The National Institute on Drug Abuse, summarizing decades of research in its Principles of Effective Treatment, states that participation in treatment for less than 90 days is of limited effectiveness for most substance-use disorders, and that better outcomes are associated with longer durations of treatment.
This matters for Kaiser SCA negotiations. Kaiser’s UM team will sometimes propose 14-to-21-day SCA approvals as a default, with step-down to Kaiser in-network IOP afterwards. The clinical-necessity case for longer SCA periods has to lean on the research: the relapse-potential and recovery-environment dimensions of ASAM 3.5 often require longer residential than 21 days, and the NIDA evidence supports continued treatment past acute withdrawal stabilization.
When concurrent review tries to cut the SCA period short, our UR and medical teams document the clinical reasoning, file additional Kaiser engagement requests, and pursue California IMR when warranted.
Kaiser Permanente is California’s largest HMO, with significant footprints in Northern and Southern CA, plus the Mid-Atlantic region, Colorado, Hawaii, Oregon-Washington, and Georgia. Some of the populations whose plans we commonly verify:
If your card lists Kaiser Permanente, Kaiser Foundation Health Plan, or KP, our UR team can walk through the SCA verification with you.
Three steps. No commitment.
Sometimes. Kaiser is a closed-system HMO; out-of-network coverage is not standard. The two pathways are Single-Case Agreement (SCA), which Kaiser negotiates case-by-case when in-network options are inadequate, and Continuity of Care exceptions for members already in active treatment with a non-Kaiser provider. Both require clinical-necessity documentation.
An SCA is a one-time contract Kaiser negotiates with an out-of-network provider when in-network options are clinically inadequate. The agreement specifies authorization length, rates, and concurrent-review requirements. Our team handles the SCA negotiation directly with Kaiser’s contracting and UM teams. Approvals can take 24 hours to 2 weeks depending on the case.
SB 855 is California’s mental-health and substance-use parity law (2020). It requires Kaiser and other CA-regulated plans to cover medically necessary SUD treatment using ASAM as the standard, and explicitly supports out-of-network coverage when in-network options are clinically inadequate. SB 855 is the legal lever behind many Kaiser SCA negotiations.
Sometimes — via SCA when Kaiser’s in-network detox capacity is unavailable, when there’s a clinical reason Kaiser’s facility isn’t appropriate, or via Continuity of Care when the member is already in active detox at a non-Kaiser facility.
We file with California Independent Medical Review (IMR) through the Department of Managed Health Care. Independent clinical reviewers evaluate whether Kaiser’s denial was appropriate under SB 855’s medical-necessity standard. The IMR reviewer’s decision is binding on Kaiser, typically within 30 days for standard reviews and 7 days for expedited urgent reviews.
Yes. The starting point for most SCA conversations is documented engagement with the member’s Kaiser primary care or behavioral-health team. A referral or written acknowledgment from the Kaiser provider documenting why non-Kaiser treatment is clinically appropriate strengthens the SCA case considerably.
Generally Kaiser prefers to prescribe MAT (buprenorphine, naltrexone, acamprosate) inside their network. Out-of-network MAT prescription via SCA is uncommon but possible when there’s a clinical reason for non-Kaiser care.
This is the strongest Continuity of Care position. Federal law and Kaiser’s own internal exception process can keep your active treatment authorized while a transition plan develops. We file the Continuity of Care request immediately on Kaiser-coverage start.
Within about 30 minutes you have a written summary of what’s covered, the prior-auth requirements, and any cost-sharing. Verification is free, confidential, and not a commitment to admit.
Kaiser Permanente, Kaiser Foundation Health Plan, and KP are trademarks of their respective owners. References are made for informational purposes only; we are not affiliated with or endorsed by Kaiser. Insurance acceptance is subject to benefit verification. Treatment outcomes vary by individual; statements about the SCA process, peer-to-peer, and appeals process describe Gev’s Recovery’s standard practices and do not guarantee specific coverage decisions by your plan. Gev’s Recovery Center · 19448 Lassen St, Northridge, CA 91324 · CA DHCS license #191288AP.